The global retinitis pigmentosa market, valued at $11.31 billion in 2024, is expected to grow to $25.87 billion by 2034, driven by gene therapy advancements, aging populations, and strategic ...

The retinitis pigmentosa market is segmented by treatment into vitamin A, docosahexaenoic acid (DHA), calcium channel blockers, gene therapy, retinal eye prosthetics and other treatments.

The global retinitis pigmentosa market, valued at $11.31 billion in 2024, is expected to grow to $25.87 billion by 2034, driven by gene therapy advancements, aging populations, and strategic industry ...

Female sex hormones can significantly enhance the progression of the rare neurodegenerative eye disease retinitis pigmentosa (RP), according to a preclinical study by researchers at UT Southwestern ...

Nanoscope’s BLA has been granted rolling review by the FDA, with the first modules already submitted. The completion of the ...

Nanoscope Therapeutics begins rolling submission of BLA to US FDA for gene-agnostic therapy, MCO-010 to treat retinitis pigmentosa: Dallas, Texas Wednesday, July 16, 2025, 14:30 H ...

AAVB-039 advances gene therapy for Stargardt disease, aiming for innovative treatments for inherited retinal disorders.

US biotech Nanoscope Therapeutics has begun a rolling submission to the American medicines regulator for MCO-010, the first ...

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced it has received a patent (US Patent No. 12,364,680) covering KIO-104 for the treatment of a wide range of ocular diseases. This includes, but ...

In her project, she will study the eye disease Retinitis Pigmentosa (RP), which is a genetic disease leading to vision loss ...

Plus Nanoscope Therapeutics applies for FDA approval and Metrocrest Hospital Authority's nonprofit grants.